Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2015 (2015), Article ID 371734, 9 pages
Research Article

Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines

1Neuroimmunology Unit, Medical School, University of Tampere, Tampere University Hospital, Biokatu 10, 33520 Tampere, Finland
2The Immunopharmacology Research Group, University of Tampere, School of Medicine and Tampere University Hospital, Medisiinarinkatu 3, 33520 Tampere, Finland
3Department of Radiology, Medical Imaging Centre, Tampere University Hospital, Teiskontie 35, 33520 Tampere, Finland
4Department of Neurology, Tampere University Hospital, Teiskontie 35, 33520 Tampere, Finland

Received 26 July 2015; Revised 30 September 2015; Accepted 18 October 2015

Academic Editor: Wolfgang Bruck

Copyright © 2015 Renuka Natarajan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background and Objective. The role of adipokines in regulation of immune responses has been recognized, but very little is known about their impact on multiple sclerosis (MS). In this study, we analysed whether the major adipokines are differentially expressed in plasma of patients with different MS subtypes and clinically isolated syndrome (CIS) and explored their association with major disease characteristics. Methods. The levels of adiponectin, adipsin, leptin, and resistin in the plasma of 80 patients with different subtypes of MS and CIS were followed up annually over the two years. The data obtained were correlated with disease activity, EDSS and volumes of T1-weighted lesions (T1-LV), and fluid attenuation inversion recovery lesions (FLAIR-LV) on MRI. Results. In MS group, a correlation was found between the level of adipsin and EDSS score at baseline (, ). In RRMS, the levels of adipsin correlated with EDSS scores (, ), T1-LV (, ), and FLAIR-LV (, ) at baseline and an increase in the T1-LV over the follow-up (, ). Associations with other adipokines were not detected. Conclusion. Our exploratory study provides novel insights on the impact of adipokines in MS and suggests that adipsin exerts predictive potential as a biomarker of neurodegeneration.